Earnings summaries and quarterly performance for CG Oncology.
Executive leadership at CG Oncology.
Arthur Kuan
Detailed
Chief Executive Officer
CEO
AB
Ambaw Bellete
Detailed
President and Chief Operating Officer
JD
Jim DeTore
Detailed
Interim Principal Financial and Accounting Officer
JP
Joshua Patterson
Detailed
General Counsel, Chief Compliance Officer and Secretary
VK
Vijay Kasturi
Detailed
Chief Medical Officer
Board of directors at CG Oncology.
Research analysts covering CG Oncology.
Recent press releases and 8-K filings for CGON.
CG Oncology Reports Q3 2025 Financial Results and Initiates BLA Submission
CGON
Earnings
Guidance Update
Product Launch
- CG Oncology reported a net loss of $43.8 million, or ($0.57) per share, for the third quarter ended September 30, 2025.
- As of September 30, 2025, the company held $680.3 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into the first half of 2028.
- The company initiated a rolling Biologics License Application (BLA) submission for cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC, with complete submission expected in 2026, and completed enrollment for the PIVOT-006 Phase 3 clinical trial.
Nov 14, 2025, 1:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more